Vinblastine, intermittent bleomycin, and single-dose cis-dichlorodiammineplatinum(II) in the management of stge III testicular cancer.
A program for treating advanced testicular cancer with vinblastine, bleomycin, and a single dose of cis-dichlorodiammineplatinum(II) was used in an attempt to reduce the toxicity of a 5-day regimen while maintaining a high response rate. In ten previously untreated and six previously treated patients, the complete remission rate was 25%. Toxic reactions were frequent, and there was one drug-related death. This single-dose cis-dichlorodiammineplatinum(II) program is ineffective in the treatment of testicular cancer. Other means for reducing toxicity will have to be considered.